BPC-157 half-life and steady state
4 h (estimated) modelled half-life, peaking 30 min after a dose. What that means for how long it lasts, how much it builds up, and when bloodwork is worth drawing.
- Also known as
- Body Protection Compound 157
- Class
- Peptides
- Modelled half-life
- 4 h — estimated half-life, limited human PK data
- Time to peak
- 30 min
- Formulation
- Aqueous (reconstituted powder)
- Cleared per dosing interval
- 98% gone, 2% still present after 24 h
- Time to steady state
- ~20 h (about five half-lives)
- Accumulation at that cadence
- 1.02× — effectively none; each dose clears before the next
- Peak-to-trough at steady state
- 57.39×
- Regulatory status
- Research compound — no FDA approval. Not for human use label.
- Monitoring panel
- No specific labs required. Monitor injection site. Liver enzymes if long-term.
- Before mixing
- Sealed powder tolerates room temperature in transit, but keep it refrigerated at 2–8 °C (36–46 °F) for anything beyond a few weeks, or frozen for months. Keep it dark — the carton it shipped in is doing a job.
- After mixing
- Once reconstituted with bacteriostatic water: refrigerate at 2–8 °C and use within about 28 days. The benzyl alcohol in bacteriostatic water is what buys that window — plain sterile water has no preservative, so a vial mixed with it should be treated as one sitting only. Kits are usually ten vials: only the one you mixed is on that 28-day clock — the sealed ones keep their own, much longer shelf life, so store them as powder, not as solution.
- What ruins it
- Do not freeze a reconstituted vial. Repeated freeze–thaw is one of the more reliable ways to degrade a peptide.
- Handling caveat
- General handling practice for this formulation. Your supplier’s own insert or COA overrides anything here.
BPC-157's four-hour half-life is an estimate, and on this compound that matters more than on most. There is no published human pharmacokinetic study to read it off; the figure is inferred from animal work and from the peptide's size and structure. Any statement about how long BPC-157 stays in circulation — including this one — is reasoning from limited data, not reporting a measurement.
Taking four hours at face value, the arithmetic is stark: a once-daily dose is gone between doses. Six half-lives fit inside twenty-four hours, so there is no accumulation and no steady state to speak of — each dose is essentially independent of the last. That is the opposite of the GLP-1 picture, and it is why the schedules people use are daily or twice daily rather than weekly.
Which raises the question the curve cannot answer. If the compound is cleared within hours, why would a daily injection do anything lasting? The mechanisms proposed for BPC-157 in the literature — angiogenesis, growth-factor receptor upregulation, effects on tendon and gut healing — are all downstream processes that take days to weeks, so a brief pulse of peptide initiating a slow biological response is at least coherent. But that is a mechanistic argument, and the evidence for it is overwhelmingly animal work. The honest framing is that the pharmacokinetics here are estimated, the pharmacodynamics are inferred, and BPC-157 has no approval for human use anywhere.
One dose
pkCurve function — a
one-compartment absorption-and-elimination model with the absorption rate fitted so the
peak lands at the published time to peak.Dosed once daily
Charted at once daily because that is the daily schedule in the app's own dosing rows. It is what the numbers below are indexed to, not a recommendation about frequency — that is a prescribing decision.
The arithmetic behind those numbers
fraction left after one interval = 2^(−6.00) = 0.016
accumulation ratio = 1 ÷ (1 − 0.016) = 1.02
time to steady state ≈ 5 × half-life = 20 h
peak-to-trough = simulated, 1.016 ÷ 0.0177 = 57.39
The accumulation ratio is a closed form; the peak-to-trough figure is not. The generator adds up enough repeated curves for the total to stop changing, then reads the highest and lowest points of the last interval — which is what steady state means in practice. The vertical axis is relative, not a concentration: the shape and the ratios carry across people, the absolute levels do not.
This compound's half-life is an estimate. The app flags it, and every number on this page inherits that. It means the published human pharmacokinetic data is limited or absent and the figure is inferred — so treat the curves as the right shape rather than the right numbers, and treat any claim about exact clearance times with the same caution.
Interaction rules that name BPC-157
From the app's own interaction data. Not exhaustive, and not a safety clearance — a combination that is not listed is one nobody has documented here, which is not the same as one that is fine. The full combination checker has the rest.
Gold Standard Injury Recovery Combination
BPC-157 and TB-500 are synergistic — BPC-157 acts locally on tissue repair mechanisms while TB-500 promotes systemic cell migration and actin upregulation. Together they represent the most comprehensive peptide approach to injury recovery.
What to watch: No specific labs. Monitor healing progress and injection sites.
LDN + BPC-157 — Synergistic Anti-inflammatory
LDN modulates immune function via TLR4 and endorphin upregulation while BPC-157 acts on gut healing and systemic inflammation. Together they address gut-brain-immune inflammation via complementary mechanisms. A popular combination in functional medicine.
What to watch: Inflammatory markers (CRP), gut symptom tracking, mood and energy self-assessment.
VIP + BPC-157 — Comprehensive Gut and Immune Stack
VIP and BPC-157 address gut inflammation via completely different mechanisms — VIP via mast cell stabilization and vasodilation, BPC-157 via tissue repair and GH receptor upregulation. Together they form a comprehensive gut and immune repair protocol.
What to watch: Inflammatory markers (TGF-beta1, C4a for CIRS), gut symptom tracking, blood pressure (VIP can cause hypotension).
The dosing rows this cadence came from
Animal-only or theoretical Reproduced from the app's entry so you can see what the chart above is indexed to. Which row applies to a particular person, if any, is a clinical decision this page does not make.
| Label | Amount | Route and frequency |
|---|---|---|
| Starting | 200-250mcg/day | Once daily SubQ near injury or orally |
| Therapeutic | 250-500mcg/day | Twice daily AM and PM |
| Gut Protocol | 250mcg orally | Twice daily fasted |
When to draw bloodwork
The panel the app records for BPC-157 is: No specific labs required. Monitor injection site. Liver enzymes if long-term.. The pharmacokinetic point is the timing rather than the list: after any change, a level takes about 20 h to settle, so a panel drawn sooner measures something still moving. And because the peak-to-trough swing here is 57.39×, when in the interval you draw changes the result materially — a result without a stated draw time relative to the last dose is hard to compare with anything. Whether a result means anything is a question for the clinician who ordered it, read against the reference range your own lab printed. The lab-marker pages cover what the individual analytes measure.
Related: the interactive half-life calculator to try other cadences, and the BPC-157 reconstitution calculator.
The app draws this curve from the doses you actually logged — your dates, your cadence — and projects seven days forward from the last one.
Save this dose to your log